Marinus Pharmaceuticals (MRNS) said Thursday that its phase 3 trial evaluating oral ganaxolone to treat seizures associated with tuberous sclerosis complex failed to meet the primary endpoint.
Shares slumped 81%, with intraday trading volume at over 37.1 million compared with a daily average of about 526,000.
Newmont (NEM) reported Q3 adjusted earnings late Wednesday that missed the average analyst estimate compiled by Capital IQ.
Shares retreated 14% as intraday trading volume jumped to over 27.2 million from a daily average of roughly 7.52 million.
Textron (TXT) reported fiscal Q3 adjusted earnings that lagged market expectations and its sales grew slower than forecast. The company also cut its adjusted EPS guidance for fiscal Q4.
Shares slid 6.8% as intraday trading volume climbed to more than 1.74 million from a daily average of about 903,000.
Price: 0.31, Change: -1.38, Percent Change: -81.89
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。